Marjorie Zettler
Marjorie Zettler, Ph.D., MPH is senior director of clinical science at Accutar Biotech and a 2022 Woman Worth Watching in STEM. An award-winning industry veteran with two decades' experience in clinical research, drug development, and regulatory strategy, she has published over 100 abstracts, manuscripts, book chapters, and patents.
ARTICLES-BY MARJORIE ZETTLER
-
![FDA-Approved-GettyImages-1186545957]( "New FDA Guidance: Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics")
4/21/2023On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). The move highlights some of the limitations that have been identified with the accelerated approval pathway and provides insight into the rationale for new FDA draft guidance.
-
FDA Issues New Guidance On Dose Optimization For Oncology Therapies2/9/2023
In January 2023, the FDA issued a new draft guidance document on optimizing the dosage of drugs and biological products for the treatment of oncologic diseases. Marjorie E. Zettler, Ph.D., MPH, executive director of clinical science at Regor Pharmaceuticals, summarizes its recommendations.
-
FDA’s RTOR Program: Draft Guidance & Insights10/4/2022
First launched in Feb. 2018 by the FDA’s Oncology Center of Excellence, the Real-Time Oncology Review (RTOR) program is intended to streamline the review process for oncology drug applications. This article summarizes the new guidance and reviews the performance of the program thus far.
-
FDA Issues Guidance On Expansion Cohorts In Clinical Trials Of Oncology Drugs4/14/2022
The FDA issued the final guidance document for first-in-human trial designs that consist of both dose escalation as well as multiple expansion cohorts to evaluate safety, anti-tumor activity, and other properties of oncology drug products, all within a single protocol. This article shares details of the guidance as well as advantages and risks of using this trial design.
-
3 Ways The FDA Is Taking Action On Lack Of Diversity In Cancer Clinical Trials3/3/2022
Beyond issuing guidance documents, what actions has the FDA taken to ensure inclusion of relevant patient populations in cancer clinical trials? And what has been the impact? This article outlines three observations regarding the agency's recent efforts.